代理人工智能用于阿尔茨海默病和相关痴呆症的自动化假设测试
Ketan S Saichandran1,2, Karim Elzokm1,3, Osman B Guney1,3
1Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA - 02118.
medRxiv : the preprint server for health sciences
|December 17, 2025
概括
一个新的模块化AI系统自动化了阿尔茨海默病和相关痴呆症 (ADRD) 研究,分析了大量数据集以有效地测试假设. 这种人工智能通过验证众多假设,随着队列规模的增长,以更高的准确性加速在人口级别痴呆症研究中的发现.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病和相关痴呆症 (ADRD) 是复杂的,多因素性疾病,在长时间内受到众多相互作用因素的影响.
- 为ADRD研究分析大型多模式数据集是劳动密集型的,阻碍了科学进步和公平的发现.
- 现有的多代理人工智能系统缺乏针对ADRD研究细微差别的具体适应.
研究的目的:
- 开发和评估一个模块化,多代理人工智能系统,适用于对阿尔茨海默病和相关痴呆症 (ADRD) 的自动分析.
- 使用大规模人口数据简化假设测试过程,解决手动数据分析的局限性.
- 通过人工智能驱动的工作流程自动化,提高痴呆症研究的效率和公平性.
主要方法:
- 一个模块化的人工智能系统被设计成专门的代理人用于数据准备,规划,分析,批评和总结.
- 该系统使用来自国家阿尔茨海默氏症协调中心 (NACC) 的数据进行了测试,其中包括48876名参与者.
- 从文献中获得的100个ADRD假设在部分样本群 (100-10,000名参与者) 和100个非ADRD对照群上进行了代测试.
主要成果:
- 人工智能系统成功验证了42.0±2.8%的ADRD假设,没有发现16.6±1.1%的证据,并认为41.4±2.3%无法测试.
- 假设验证率随着队列的大小显著增加,从10.4% (n=100) 增加到35.4% (n=10,000).
- 对照分析显示,不可测试假设的比例很高 (85.2±0.6%),表明系统的特异性.
结论:
- 开发的AI系统展示了在痴呆症研究中自动化数据分析的强大新范式.
- 这种人工智能有助于在阿尔茨海默氏症和相关痴呆症的人口层面调查中取得快速进展.
- 该系统的模块化设计和代测试方法在复杂的生物研究中提高了效率和可靠性.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
